Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mike Ward
Medicxi's new $300m venture fund will benefit from the expertise of former GSK R&D leader Moncef Slaoui, while ex-CEO Witty will inform portfolio strategy at Hatteras. Also, Kaleido hires past Cubist CEO and brings VC funding to $65m, while Gilead sells $3bn in debt to fund Kite deal.
Download this Special Report, written by Mike Ward, Chief Content Officer for Informa Pharma Intelligence Insights Portfolio, to learn how growing a life science business involves big decisions and formidable challenges the world over. The discussion, among several c-suite executives from a number of companies, focuses on how access to the right kind of capital, scientific and business talent, and a supportive political and regulatory environment are all important factors for achieving ambitions.
Repare Therapeutics Inc., a Boston and Toronto-based cancer biotech, focusing on synthetic lethality, has hit the ground running with a $68m series A round from seasoned venture capitalists.
In the spirit of the BIO International Convention's partnering focus, Scrip covered a dealmaker survey and spoke to Bayer about some of its business development priorities on day two of the annual convention. We also report on a payer perspective, post-Brexit EMA rumors and investments in vaccines.
The biotech industry's annual confab, already known as a stage for countries and regions to play up their potential as industry hubs, is now the venue for rumors over who will host the headquarters for the European Medicines Agency post-Brexit.
Alphabet's Verily Life Sciences intends to increase its exposure to European biotech by joining Novartis and the European Investment Fund as cornerstone investors in Medicxi Growth 1 (MG1), a $300m fund launched by VC firm Medicxi to focus on late-stage private life science companies.